Patents by Inventor Takashi Nishizato
Takashi Nishizato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11707451Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.Type: GrantFiled: December 8, 2020Date of Patent: July 25, 2023Assignee: ASTELLAS PHARMA INC.Inventors: Yuuki Takaishi, Soichiro Nakamura, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Kazuhiro Sako
-
Publication number: 20210322387Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25 C is disclosed.Type: ApplicationFiled: November 19, 2020Publication date: October 21, 2021Inventors: YUUKI TAKAISHI, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, SOICHIRO NAKAMURA, KAZUHIRO SAKO
-
Publication number: 20210085654Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.Type: ApplicationFiled: December 8, 2020Publication date: March 25, 2021Inventors: YUUKI TAKAISHI, SOICHIRO NAKAMURA, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, KAZUHIRO SAKO
-
Patent number: 10842780Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.Type: GrantFiled: February 14, 2017Date of Patent: November 24, 2020Assignee: ASTELLAS PHARMA INC.Inventors: Yuuki Takaishi, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Soichiro Nakamura, Kazuhiro Sako
-
Patent number: 9775832Abstract: Provided is a pharmaceutical composition for oral administration enabling improved solubility, improved dissolution properties, and improved oral absorbability of (2R)—N-({5-[3-(2,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazole-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydroxypropane imide amide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, as well as size reduction. The pharmaceutical composition for oral administration contains an amorphous form of compound A or its pharmaceutically acceptable salt, and a polymer.Type: GrantFiled: June 24, 2015Date of Patent: October 3, 2017Assignee: ASTELLAS PHARMA INC.Inventors: Hiroyuki Kojima, Masakazu Miyazaki, Mare Nishiura, Takashi Nishizato
-
Publication number: 20170231965Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.Type: ApplicationFiled: February 14, 2017Publication date: August 17, 2017Applicant: ASTELLAS PHARMA INC.Inventors: YUUKI TAKAISHI, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, SOICHIRO NAKAMURA, KAZUHIRO SAKO
-
Publication number: 20170143678Abstract: Provided is a pharmaceutical composition for oral administration enabling improved solubility, improved dissolution properties, and improved oral absorbability of (2R)—N-({5-[3-(2,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazole-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydroxypropane imide amide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, as well as size reduction. The pharmaceutical composition for oral administration contains an amorphous form of compound A or its pharmaceutically acceptable salt, and a polymer.Type: ApplicationFiled: June 24, 2015Publication date: May 25, 2017Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki KOJIMA, MASAKAZU MIYAZAKI, MARE NISHIURA, TAKASHI NISHIZATO
-
Publication number: 20160184275Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.Type: ApplicationFiled: September 28, 2009Publication date: June 30, 2016Applicant: ASTELLAS PHARMA INC.Inventors: YUUKI TAKAISHI, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, SOICHIRO NAKAMURA, KAZUHIRO SAKO
-
Publication number: 20110128557Abstract: There is provided a tablet printing apparatus that can perform printing at a high speed on tablets arbitrarily supplied in volume at irregular intervals and has a high printing quality. A tablet printing apparatus 1 for multicolor printing on tablets T comprises a conveying belt 24 for conveying the tablets T in a moving direction A1-A2, an inkjet printer 42 disposed in the middle of the moving direction A1-A2 of the conveying belt 24 for performing non-contact printing onto surfaces of the tablets T conveyed by the conveying belt 24, an encoder 28 and a tablet sensor 29 for detecting moving positions of the tablets T conveyed by the conveying belt 24, and a unit control substrate 32 for controlling printing timing on the tablets T of the inject printer 42 or 46 based on the moving conditions or/and the moving positions of the tablets T detected by the encoder 28 and the tablet sensor 29.Type: ApplicationFiled: August 22, 2008Publication date: June 2, 2011Applicants: ASTELLAS PHARMA INC., DAIICHI JITSUGYO CO., LTD., DAIICHI JITSUGYO VISWILL CO., LTD., MASTERMIND CO., LTD.Inventors: Noriyuki Kinoshita, Takao Mizumoto, Keizo Baba, Takashi Nishizato, Syuya Kawahama, Hideyuki Tomoda, Yoshihide Muramatsu, Shiro Hatano, Fumihiro Ogawa, Chizuo Ozawa
-
Publication number: 20100144807Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 5 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.Type: ApplicationFiled: September 28, 2009Publication date: June 10, 2010Applicant: Astellas Pharma IncInventors: Yuuki Takaishi, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Soichiro Nakamura, Kazuhiro Sako